CompletedPhase 1

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

United States26 participantsStarted 2016-10

Plain-language summary

This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.

Who can participate

Age range1 Year – 21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-A serum creatinine based on age/gender as follows: Age Maximum Serum Creatinine (mg/dL) Male Female
✓. to \< 2 years 0.6 0.6
✓. to \< 6 years 0.8 0.8
✓-Creatinine clearance ≥ 70 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.

What they're measuring

Dose Limiting Toxicity

Timeframe: 2 years

Trial details

NCT IDNCT02909777

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Lymphoma trials